Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Dec;5(12):a021451. doi: 10.1101/cshperspect.a021451

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved

PMC Copyright notice

Figure 2. — Strategies for therapeutic vaccination and/or immunomodulation in patients with chronic hepatitis B (CHB). Option 1: Combination of antiviral treatment nucleos(t)ide and prime–boost vaccination. Option 2: Combination of antiviral treatment nucleos(t)ide and anti-programmed death-ligand 1 (PD-L1). Option 3: Triple therapy with antiviral treatment nucleos(t)ide and prime–boost vaccination and anti-PD-L1. HBcAg, Hepatitis B core antigen; MVA, modified vaccinia Ankara; HBsAg, hepatitis B surface antigen; MVA, modified vaccinia Ankara; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HBeAG, hepatitis B e antigen; ALT, alanine aminotransferase; IFN, interferon.